We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Seeks Feedback on Best Practices for Postmarket Surveillance
FDA Seeks Feedback on Best Practices for Postmarket Surveillance
The FDA invited comments on a draft guidance that outlines the agency’s best practices for postmarket safety surveillance for drugs and biologics, including product quality issues (PQIs).